Skip to Main Content

Advertisement

Skip Nav Destination
Issue Cover
Current Issue
Volume 12,
Issue 5
1 May 2022

About the Journal

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal

Noted This Week

The FDA approved azacitidine (Vidaza; Celgene) for children with newly diagnosed juvenile myelomonocytic leukemia. The decision was based on the AZA-JMML-001 trial, in which 18 patients received azacitidine prior to hematopoietic stem cell (HSC) transplantation. Three patients experienced clinical complete remission (CR) and six experienced clinical partial remission, with a median time to response of 1.2 months; 94% underwent HSC transplantation, with a median time to transplantation of 4.6 months.

More Noted This Week, May 20–26   »

Close Modal

or Create an Account

Close Modal
Close Modal